Browse ILF3

Summary
SymbolILF3
Nameinterleukin enhancer binding factor 3, 90kDa
Aliases NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus, nucleolus Cytoplasm Nucleus Note=Localizes in the cytoplasm in response to viral infection. The unphosphorylated form is retained in the nucleus by ILF2. Phosphorylation at Thr-188 and Thr-315 causes the dissociation of ILF2 from the ILF2-ILF3 complex resulting in a cytoplasmic sequestration of ILF3. Localized in cytoplasmic mRNP granules containing untranslated mRNAs.
Domain PF00035 Double-stranded RNA binding motif
PF07528 DZF domain
Function

RNA-binding protein that plays an essential role in the biogenesis of circular RNAs (circRNAs) which are produced by back-splicing circularization of pre-mRNAs. Within the nucleus, promotes circRNAs processing by stabilizing the regulatory elements residing in the flanking introns of the circularized exons. Plays thereby a role in the back-splicing of a subset of circRNAs (PubMed:28625552). As a consequence, participates in a wide range of transcriptional and post-transcriptional processes. Upon viral infection, ILF3 accumulates in the cytoplasm and participates in the innate antiviral response (PubMed:21123651). Mechanistically, ILF3 becomes phosphorylated and activated by the double-stranded RNA-activated protein kinase/PKR which releases ILF3 from cellular mature circRNAs. In turn, unbound ILF3 molecules are able to interact with and thus inhibit viral mRNAs (PubMed:21123651, PubMed:28625552).

> Gene Ontology
 
Biological Process GO:0006417 regulation of translation
GO:0009615 response to virus
GO:0010608 posttranscriptional regulation of gene expression
GO:0017148 negative regulation of translation
GO:0019058 viral life cycle
GO:0019079 viral genome replication
GO:0034248 regulation of cellular amide metabolic process
GO:0034249 negative regulation of cellular amide metabolic process
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0045069 regulation of viral genome replication
GO:0045071 negative regulation of viral genome replication
GO:0048525 negative regulation of viral process
GO:0050792 regulation of viral process
GO:0051607 defense response to virus
GO:0098542 defense response to other organism
GO:1903900 regulation of viral life cycle
GO:1903901 negative regulation of viral life cycle
Molecular Function GO:0003725 double-stranded RNA binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolILF3
Nameinterleukin enhancer binding factor 3, 90kDa
Aliases NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ILF3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolILF3
Nameinterleukin enhancer binding factor 3, 90kDa
Aliases NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ILF3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolILF3
Nameinterleukin enhancer binding factor 3, 90kDa
Aliases NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ILF3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0430.79
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0680.98
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1250.951
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1460.595
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0070.998
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3410.926
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0950.834
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0070.998
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.240.921
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2280.901
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8750.744
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.10.0874
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ILF3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91633.3033.30.0365
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59400400.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolILF3
Nameinterleukin enhancer binding factor 3, 90kDa
Aliases NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ILF3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolILF3
Nameinterleukin enhancer binding factor 3, 90kDa
Aliases NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ILF3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ILF3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolILF3
Nameinterleukin enhancer binding factor 3, 90kDa
Aliases NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ILF3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolILF3
Nameinterleukin enhancer binding factor 3, 90kDa
Aliases NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ILF3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolILF3
Nameinterleukin enhancer binding factor 3, 90kDa
Aliases NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ILF3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolILF3
Nameinterleukin enhancer binding factor 3, 90kDa
Aliases NF90; MPHOSPH4; DRBP76; NFAR-1; M-phase phosphoprotein 4; interleukin enhancer binding factor 3, 90kD; CBTF; ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ILF3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.